【医疗行业研报】瑞信-中国医疗保健行业-2022年中国医疗保健展望：冬天来了，春天还会远吗？_市场营.pptxVIP

China Healthcare Outlook 2022 If Winter comes, can Spring be far behind?;;China Healthcare Outlook 2022 2022 Key Calls At-A-Glance;;;;;;;;;;;;;16;Translational science driving development innovation Increase in new drug IND in China;Success rate (from Ph1 to approval);19;More scrutiny possible on innovation from financial market Flat number of healthcare IPOs expected in 2022;21;22;23;Innovation to drive divergence in the sector Stock implications;;26;27;Source: Credit Suisse, Company data;As of November 2021, there were a total of 84 license-in deals in China. Among these, 74 were license